The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Jonathan M. Meyer

Department of Psychiatry

University of California

La Jolla

CA 92093

USA

[email]@ucsd.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Psychiatry, University of California, La Jolla, CA 92093, USA. 2002 - 2010
  • Veterans Affairs San Diego Healthcare System, La Jolla, USA. 2005 - 2009
  • VA San Diego Healthcare System, USA. 2005
  • University of California, San Diego VAMC (MC 116A), 3350 La Jolla Village Drive, San Diego, USA. 2004
  • San Diego VA Medical Center, La Jolla, CA 92161, USA. 2004

References

  1. Antipsychotics and metabolics in the post-CATIE era. Meyer, J.M. Curr. Top. Behav. Neurosci (2010) [Pubmed]
  2. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Meyer, J.M., McEvoy, J.P., Davis, V.G., Goff, D.C., Nasrallah, H.A., Davis, S.M., Hsiao, J.K., Swartz, M.S., Stroup, T.S., Lieberman, J.A. Biol. Psychiatry (2009) [Pubmed]
  3. Lurasidone: a new drug in development for schizophrenia. Meyer, J.M., Loebel, A.D., Schweizer, E. Expert. Opin. Investig. Drugs (2009) [Pubmed]
  4. The metabolic syndrome and schizophrenia. Meyer, J.M., Stahl, S.M. Acta. Psychiatr. Scand (2009) [Pubmed]
  5. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. Meyer, J.M., Rosenblatt, L.C., Kim, E., Baker, R.A., Whitehead, R. J. Clin. Psychiatry (2009) [Pubmed]
  6. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Meyer, J.M., Davis, V.G., McEvoy, J.P., Goff, D.C., Nasrallah, H.A., Davis, S.M., Daumit, G.L., Hsiao, J., Swartz, M.S., Stroup, T.S., Lieberman, J.A. Schizophr. Res. (2008) [Pubmed]
  7. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Meyer, J.M., Davis, V.G., Goff, D.C., McEvoy, J.P., Nasrallah, H.A., Davis, S.M., Rosenheck, R.A., Daumit, G.L., Hsiao, J., Swartz, M.S., Stroup, T.S., Lieberman, J.A. Schizophr. Res. (2008) [Pubmed]
  8. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial. Meyer, J.M. J. Clin. Psychiatry (2007) [Pubmed]
  9. Antipsychotic safety and efficacy concerns. Meyer, J.M. J. Clin. Psychiatry (2007) [Pubmed]
  10. Prevalence of the metabolic syndrome in veterans with schizophrenia. Meyer, J., Loh, C., Leckband, S.G., Boyd, J.A., Wirshing, W.C., Pierre, J.M., Wirshing, D. J. Psychiatr. Pract (2006) [Pubmed]
  11. Bone mineral density in male schizophrenia patients: a review. Meyer, J.M., Lehman, D. Ann. Clin. Psychiatry (2006) [Pubmed]
  12. Lithium toxicity after switch from fosinopril to lisinopril. Meyer, J.M., Dollarhide, A., Tuan, I.L. Int. Clin. Psychopharmacol (2005) [Pubmed]
  13. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Meyer, J.M., Nasrallah, H.A., McEvoy, J.P., Goff, D.C., Davis, S.M., Chakos, M., Patel, J.K., Keefe, R.S., Stroup, T.S., Lieberman, J.A. Schizophr. Res. (2005) [Pubmed]
  14. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Meyer, J.M., Pandina, G., Bossie, C.A., Turkoz, I., Greenspan, A. Clin. Ther (2005) [Pubmed]
  15. Quetiapine-induced diabetes with metabolic acidosis. Meyer, J.M., Leckband, S.G., Loh, C., Moutier, C.Y. Int. Clin. Psychopharmacol (2004) [Pubmed]
  16. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Meyer, J.M., Koro, C.E. Schizophr. Res. (2004) [Pubmed]
  17. Treating the mind and body in schizophrenia: risks and prevention. Meyer, J.M. CNS. Spectr (2004) [Pubmed]
  18. Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital. Meyer, J.M. J. Clin. Psychiatry (2003) [Pubmed]
  19. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Meyer, J.M. J. Clin. Psychiatry (2002) [Pubmed]
  20. Awareness of obesity and weight issues among chronically mentally ill inpatients: a pilot study. Meyer, J.M. Ann. Clin. Psychiatry (2002) [Pubmed]
 
WikiGenes - Universities